isopropyl-(2-methyl-cyclohexyl)-amine | 55794-83-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: isopropyl-(2-methyl-cyclohexyl)-amine
• 英文别名: 2-methyl-N-(propan-2-yl)cyclohexan-1-amine；2-methyl-N-propan-2-ylcyclohexan-1-amine
• CAS: 55794-83-7
• 化学式: C₁₀H₂₁N
• mdl: MFCD11139106
• 分子量: 155.283
• InChiKey: UPHMFGWCRAJMPC-UHFFFAOYSA-N

物化性质

• 沸点：
  82.4 °C(Press: 10 Torr)
• 密度：
  0.8266 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  邻甲苯胺 在 kieselguhr 、 镍 、 异丙醇 作用下， 180.0 ℃ 、17.16 MPa 条件下， 生成 isopropyl-(2-methyl-cyclohexyl)-amine
  参考文献：
  名称：

  Preparation of N-Alkyl-2-methylcyclohexylamines

  摘要：

  DOI：

  10.1021/ja01111a506

文献信息

• [EN] PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA<br/>[FR] COMPOSÉS DE PYRIMIDINONE ET MÉTHODES DE PRÉVENTION ET DE TRAITEMENT DE LA GRIPPE
  申请人：ST JUDE CHILDRENS RES HOSPITAL

  公开号：WO2012151567A1

  公开（公告）日：2012-11-08

  In one aspect, the invention relates to novel, broad-spectrum anti-viral, pyrimidinone compounds, methods of use, compositions and kits useful in treating and/or preventing influenza. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及新颖的、广谱抗病毒的嘧啶酮化合物，以及用于治疗和/或预防流感的方法、组合物和工具包。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着对本发明的限制。
• Highly efficient one-pot multi-directional selective hydrogenation and N-alkylation catalyzed by Ru/LDH under mild conditions
  作者：Sishi Zhang、Jie Xu、Hongmei Cheng、Cuicui Zang、Bin Sun、Heyan Jiang、Fengxia Bian

  DOI：10.1016/j.apcata.2020.117536

  日期：2020.4

  multi-directional superb chemoselectivity to aromatic amines, alicyclic amines as well as N-alkyl aliphatic amines could be achieved with excellent catalytic activity and recyclability by tuning reaction conditions over 5wt%Ru/LDH-2. Additionally, this catalytic system also exhibited attractive activity and multi-directional chemoselectivity in the hydrogenation of quinoline and its derivatives with solvents

  绿色化学倡导的原子经济，无毒，无害和多向选择性等问题日益成为研究的热点和难点。在本文中，我们提出了一种高效，一站式串联且易于操作的方法，通过该方法，我们可以使用芳族硝基化合物为原料直接生产各种多方向的选择性氢化胺或N-烷基脂肪族胺。具有层状介孔结构，良好分散的小Ru纳米颗粒和对Ru NPs的LDH稳定化的Ru / LDH用作催化剂。值得注意的是，通过在5wt％Ru / LDH-2上调节反应条件，可以以优异的催化活性和可回收性实现对芳族胺，脂环族胺以及N-烷基脂肪族胺的多方向优异的化学选择性。另外，在用不同极性的溶剂氢化喹啉及其衍生物时，该催化体系还表现出有吸引力的活性和多方向化学选择性。对5,6,7,8-四氢喹啉衍生物的化学选择性可高达95.6％。
• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170044100A1

  公开（公告）日：2017-02-16

  The present invention provides novel indoleamide compounds for treating tuberculosis, including drug-resistant M - tuberculosis, compositions comprising the indoleamides and methods of using the indoleamides in conjunction with other biologically active agents for the treatment of tuberculosis in a subject in need thereof.
• ERK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170266167A1

  公开（公告）日：2017-09-21

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.